Biotech Company Partners With University of Colorado to Research Experimental HIV/AIDS Treatment
January 9, 2008
Azusa, Calif.-based Viral Genetics has agreed to partner with the University of Colorado-Colorado Springs to conduct research into an experimental HIV/AIDS treatment, the Colorado Springs Gazette reports. According to the agreement, Karen Newell, an associate biology professor at the university, will work over the next year to explain how the Viral Genetics-developed compound VGV-1 is effective in treating some people living with the disease.
Newell's "basic scientific research and discoveries appear to compliment (sic) the over 10 years of human clinical experience we have," Haig Keledjian, Viral Genetics co-founder and president, said in a release, adding, "The acquisition of these rights holds significant promise to finally" determine exactly how and why the compound works. "We not only want to show how and why the compound works, but also improve the product so that it works on all of the patients rather than just some of them," Newell said (Heilman, Colorado Springs Gazette, 1/7).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.